Investing in Late-Life Brain Capital.

Aging Brain health Innovation Mental disorders Neuroscience Psychiatry

Journal

Innovation in aging
ISSN: 2399-5300
Titre abrégé: Innov Aging
Pays: England
ID NLM: 101703706

Informations de publication

Date de publication:
2022
Historique:
received: 05 08 2021
entrez: 23 5 2022
pubmed: 24 5 2022
medline: 24 5 2022
Statut: epublish

Résumé

Within many societies and cultures around the world, older adults are too often undervalued and underappreciated. This exacerbates many key challenges that older adults may face. It also undermines the many positive aspects of late life that are of tremendous value at both an individual and societal level. We propose a new approach to elevate health and well-being in late life by optimizing late-life Brain Capital. This form of capital prioritizes brain skills and brain health in a brain economy, which the challenges and opportunities of the 21st-century demands. This approach incorporates investing in late-life Brain Capital, developing initiatives focused on building late-life Brain Capital.

Identifiants

DOI: 10.1093/geroni/igac016 PMID: 35602311 PMC: PMC9116879
pubmed: 35602311
doi: 10.1093/geroni/igac016
pii: igac016
pmc: PMC9116879
doi:

Types de publication

Journal Article

Langues

eng

Pagination

igac016

Subventions

Organisme : NIA NIH HHS
ID : P30 AG066518
Pays : United States
Organisme : NIA NIH HHS
ID : P20 AG068053
Pays : United States
Organisme : NIA NIH HHS
ID : R35 AG071476
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS093334
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG072980
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM109025
Pays : United States
Organisme : NICHD NIH HHS
ID : P50 HD103555
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of The Gerontological Society of America.

Références

Alzheimers Dement. 2022 Jul;18(7):1396-1407
pubmed: 34569702
Am J Geriatr Psychiatry. 2020 Jun;28(6):591-596
pubmed: 32276828
Neuron. 2021 May 5;109(9):1430-1432
pubmed: 33957073
Mol Psychiatry. 2021 Jan;26(1):3-22
pubmed: 33100330
Front Public Health. 2021 Mar 16;9:641754
pubmed: 33796498
Science. 2020 Jun 5;368(6495):1044
pubmed: 32499420

Auteurs

Walter D Dawson (WD)

Department of Neurology, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA.

Erin Smith (E)

Global Brain Health Institute at University of California, San Francisco (UCSF), San Francisco, California, USA.

Laura Booi (L)

Global Brain Health Institute at University of California, San Francisco (UCSF), San Francisco, California, USA.

Maia Mosse (M)

Department of Medicine, Stanford Hospital, Stanford, California, USA.

Helen Lavretsky (H)

Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA), Los Angeles, California, USA.

Charles F Reynolds (CF)

Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Jeffrey Cummings (J)

Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, Las Vegas, Nevada, USA.

Patrick Brannally (P)

Alzheimer's Disease Data Initiative, Gates Ventures, Redwood City, California, USA.

William Hynes (W)

Department of Medicine, Stanford Hospital, Stanford, California, USA.

Eric J Lenze (EJ)

Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA.

Facundo Manes (F)

Institute of Cognitive and Translational Neuroscience (INCYT), INECO Foundation, Favaloro University, Buenos Aires, Argentina.

Rym Ayadi (R)

Euro-Mediterranean Economists Association, Barcelona, Spain.

Lori Frank (L)

RAND Corporation, Arlington, Virginia, USA.

Sandra Bond Chapman (SB)

Center for BrainHealth®, The University of Texas at Dallas, Dallas, Texas, USA.

Ian H Robertson (IH)

Global Brain Health Institute at University of California, San Francisco (UCSF), San Francisco, California, USA.

Lori Rubenstein (L)

Australian Research Alliance for Children and Youth (ARACY), Canberra, Australian Capital Territory, Australia.

Jorge Jraissati (J)

IESE Center for Public Leadership and Government, IESE Business School, Madrid, Spain.

Agustin Ibáñez (A)

Global Brain Health Institute at University of California, San Francisco (UCSF), San Francisco, California, USA.

Howard Fillit (H)

Alzheimer's Drug Discovery Foundation (ADDF), New York City, New York, USA.

Dilip V Jeste (DV)

Departments of Psychiatry and Neurosciences, University of California San Diego, La Jolla, California, USA.
ORCID: 0000-0002-1161-7351

Anitha Rao (A)

Neurocern, Chicago, Illinois, USA.

Michael Berk (M)

IMPACT, the Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Victoria, Australia.
ORCID: 0000-0002-5554-6946

Eric A Storch (EA)

Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA.

Antonella Santuccione Chadha (A)

Biogen, Cambridge, Massachusetts, USA.

Harris A Eyre (HA)

IMPACT, the Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Victoria, Australia.

Classifications MeSH